COVID-19 vaccine, ChAdOx1-S [recombinant]

(Vaxzevria®)

COVID-19 vaccine, ChAdOx1-S [recombinant]

Latest News

loading GIF

Drug updated on 5/17/2024

Dosage FormInjection (intramuscular; 0.5 mL)
Drug ClassVaccines
Ongoing and
Completed Studies
ClinicalTrials.gov

Indication

  • Indicated for active immunization of individuals 18 years of age and older for the prevention of coronavirus disease 2019 (COVID-19).

Summary
This AI-generated content is provided without warranty and may be inaccurate or outdated; it should be used only as a research starting point, with no liability accepted for reliance on it. Learn more.

  • Vaxzevria (COVID-19 vaccine, ChAdOx1-S [recombinant]) is indicated for the active immunization of individuals 18 years and older for the prevention of coronavirus disease 2019 (COVID-19).
  • Fourteen studies were analyzed to gather information about Vaxzevria.
  • Vaxzevria has been found effective and safe in the Autoimmune Rheumatic Diseases (ARD) population. However, responses could be suboptimal in individuals on certain immunomodulatory medications or with specific comorbidities.
  • In African populations, Vaxzevria demonstrated wide-ranging efficacy against COVID-19 and its variants, with adverse events generally being mild to moderate, supporting the safety profile of this vaccine.
  • Vaccine effectiveness, including that of Vaxzevria for preventing infections, hospitalizations, and mortality, tends to decrease over time. As a result, booster doses are recommended.
  • Rare instances have linked Vaxzevria with Transverse Myelitis (TM), especially among higher age groups, where recovery was poorer compared to others.
  • Vaxzevria has also been associated with Vaccine-induced Immune Thrombotic Thrombocytopenia (VITT), a condition that presents challenges in diagnosis but remains rare relative to the number of doses administered.
  • Thromboembolic events post-vaccination have occurred after administering this vaccine; some cases resulted in fatality, emphasizing the need for awareness and prompt management.

Product Monograph / Prescribing Information

Document TitleYearSource
Vaxzevria (COVID-19 Vaccine (ChAdOx1-S [recombinant]) Prescribing Information.2022AstraZeneca Canada Inc., Mississauga, Ontario

Systematic Reviews / Meta-Analyses

Document TitleYearSource
Efficacy and safety of mRNA and AstraZeneca COVID-19 vaccines in patients with autoimmune rheumatic diseases: a systematic review.2023Vaccine
Safety and efficacy of COVID-19 vaccine in Africa: systematic review.2023Infection and Drug Resistance
Long-term effectiveness of COVID-19 vaccines against infections, hospitalisations, and mortality in adults: findings from a rapid living systematic evidence synthesis and meta-analysis up to December, 2022.2023The Lancet Respiratory Medicine
Clinical characteristics, radiological features and prognostic factors of transverse myelitis following COVID-19 vaccination: a systematic review.2022Multiple Sclerosis and Related Disorders
Thrombosis patterns and clinical outcome of covid-19 vaccine-induced immune thrombotic thrombocytopenia: a systematic review and meta-analysis.2022International Journal of Infectious Diseases
A systematic review of vaccine-induced thrombotic thrombocytopenia in individuals who received COVID-19 adenoviral-vector-based vaccines.2022Journal of Thrombosis and Thrombolysis
Duration of effectiveness of vaccines against SARS-CoV-2 infection and COVID-19 disease: results of a systematic review and meta-regression.2022The Lancet
Thrombotic thrombocytopenic purpura (TTP) after COVID-19 vaccination: a systematic review of reported cases.2022Thrombosis Research
Outcomes of patients with thromboembolic events following coronavirus disease 2019 AstraZeneca vaccination: a systematic review and meta-analysis.2022Blood Coagulation & Fibrinolysis
Cerebral venous sinus thrombosis following COVID-19 vaccination: a systematic review.2022Journal of Primary Care & Community Health
Autopsy findings and causality relationship between death and COVID-19 vaccination: a systematic review.2021Journal of Clinical Medicine
COVID-19 vaccine-related thrombosis: a systematic review and exploratory analysis.2021Frontiers in Immunology
Duration of effectiveness of vaccines against SARS-CoV-2 infection and COVID-19 disease: results of a systematic review and meta-regression.2021The Lancet
Vaccine-induced immune thrombotic thrombocytopenia and cerebral venous sinus thrombosis post COVID-19 vaccination; a systematic review.2021Journal of Neurological Sciences